STADA Arzneimittel (ETR:SAZ) Rating Reaffirmed
Equity analysts at Independent Research GmbH now has a EUR 37.00 price target on STADA Arzneimittel (ETR:SAZ). Independent Research GmbH and their recent price target may suggest a potential upside of 2.21% from the company’s stock close price. The rating has been disclosed to clients in a note on Tuesday morning.
From a total of 11 analysts covering STADA Arzneimittel (ETR:SAZ) stock, 3 rate it a ”Buy”, 1 a “Sell”, and 7 a ”Hold”. This means that 27% of the ratings are positive. The highest target price is €42 while the lowest target price is €29. The mean of all analyst targets is €35.67 with a -1.63% below today’s (€36.26) stock price. STADA Arzneimittel was the topic of 14 analyst reports since July 22, 2015 according to the firm StockzIntelligence Inc. Deutsche Bank upgraded shares on December 1 to “Buy” rating. JP Morgan maintained shares with “Neutral” rating and €35.40 target share price in a report from an October 23. Kepler Cheuvreux upgraded SAZ stock in a recent report from November 14 to “Buy” rating. Jefferies maintained the rating on September 26. Jefferies has a “Hold” rating and a €33 price target on shares. Finally, Oddo & Cie upgraded the stock to “Buy” rating in a report issued on a November 11.
The stock increased 1.70% or EUR 0.6 on December 7, striking EUR 36.26. Approximately 189,706 shares of stock traded hands. STADA Arzneimittel AG (ETR:SAZ) has risen 12.40% since May 11, 2015 and is uptrending. It has outperformed by 13.47% the S&P500.
Stada Arzneimittel AG is a Germany-based holding firm active in the pharmaceutical sector and healthcare market. The company has a market cap of 2.26 billion EUR. The Firm develops and markets products with off-patent active pharmaceutical ingredients. It has 40.27 P/E ratio. The Company’s primary business divisions are Generics and Branded Products.